Today's News |
AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research with Sanofi Pasteur
Monday, July 10, 2017Company Profile | Follow Company
AbCellera announces a project with Sanofi Pasteur to apply its human antibody discovery and immune profiling technology for the research and development of next-generation influenza vaccines.
Vancouver, BC, July 10, 2017--(T-Net)--AbCellera announced that it has entered into a collaborative research effort with Sanofi Pasteur, a global leader in the development and sale of vaccines for seasonal influenza.
The project will use AbCellera's single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with desired binding profiles to various influenza strains.
Carl Hansen, CEO of AbCellera, commented, “AbCellera's platform is a powerful approach for human immune profiling and antibody discovery.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera's lead technology is a proprietary single cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans.
Other Recent Company News |
|||||||||||||||||||
|